Browse drugs

…ommon Grade 1/2 events occurred in ≤20% of patients.Conclusions Imneskibart + low-dose SC aldesleukin possess a unique mechanism of action …

… his 60s with metastatic Merkel cell carcinoma was treated with avelumab. After 8 months, he achieved complete resolution of cutaneous l…

…Ref Funder ID: 10.13039/100004755), which provides avelumab and tuvusertib.Trial Registration NCT05947500References Vendetti FP, Karukonda…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…cancer immunotherapy clinical trials (OAK and POPLAR, comparing atezolizumab to docetaxel in non-small cell lung cancer) as well as a separa…

…pre-treatment longitudinal changes following the combination of avelumab with utomilumab (a 4-1BB agonist) (arm A), PF-04518600 (an OX40…

…l in athymic nude mice was utilized to evaluate the efficacy of tuvusertib and N-803 combination therapy in vivo. Tuvusertib and avelumab …

…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…